November 2019: Quanta Announces Poster Presentation at ASN Kidney Week 2019

Quanta Dialysis Technologies, a British medical technology company developing a personal haemodialysis system (SC+) for patient use at home and in the clinic, announces that the Company will be presenting a poster at the ASN Conference, reporting on results from an experimental pulsatile push-pull flow mechanism. These results demonstrate feasibility of using a small and easy-to-use haemodialysis system like SC+ to deliver enhanced solute clearance comparable to hemodiafiltration without any added complexity.

Click Here To Read The Full Press Release


August 2019: Quanta Appoints Benchmark Electronics as Manufacturing Partner

Quanta Dialysis Technologies, a British medical technology company developing a personal haemodialysis system (SC+) for patient use in clinic and the home, today announces that it has selected Benchmark Electronics Inc., a global provider of manufacturing, engineering and design services, as its production partner for the SC+ haemodialysis machine. Benchmark has over 40 years of experience working with medical device companies. With specific expertise in complex medical systems, fluidics and electronics assembly, Benchmark is the ideal partner for Quanta.

Click Here To Read The Full Press Release


August 2019: Quanta Begins Study in US to Support FDA Submission

Quanta Dialysis Technologies, a British medical technology company developing a personal haemodialysis system (SC+) for patient use in clinic and the home, today announces that it has begun human factors testing of SC+ in the United States with Design Science, a leading specialist in medical device usability. Human factors testing (HFT) is used to assess how intended users interact with a medical device in representative real-world conditions. The HFT study will be conducted in the US with end users representing a diverse range of age and ethnicity of the adult US population, to evaluate the safety and effective use of Quanta's updated SC+ system. This represents an important step towards Quanta's 510(k) submission to the FDA planned for later this year and, ultimately, US market entry.

Click Here To Read The Full Press Release


July 2019: Quanta Raises $48 million in Series C Funding Round

Quanta Dialysis Technologies, a British medical technology company developing a personal haemodialysis system (SC+) for patient use in clinic and the home, today announces that it has successfully raised £38 million ($48 million) in a first closing of its Series C funding round. Proceeds will be used to fund the UK commercial launch of SC+ and a 510(k) submission to the FDA later this year.

Click Here To Read The Full Press Release


July 2019: Quanta Supports the American Kidney Health Initiative

A major overhaul of American kidney health was announced yesterday by the Trump Administration and the US Department of Health and Human Services. This initiative has enormous potential to improve the lives of American kidney patients by promoting better screening and prevention, making organ transplantation more accessible and providing dialysis patients with greater choice and better access to home therapies. Importantly, this includes proposals for Medicare to incentivise increased utilisation of home dialysis through payment mechanisms.

Click Here To Read The Full Thought Piece


June 2019: Quanta to Exhibit at the 56th Annual ERA-EDTA Congress

Quanta Dialysis Technologies, a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that the Company will be exhibiting at the 56th Annual European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Thursday 13th to Sunday 16th June, at the Hungexpo in Budapest, Hungary, at booth number 1.040.

Click Here To Read The Full Press Release


April 2019: Results From SC+ Human Factors Testing Published In Hemodialysis International

Quanta Dialysis Technologies, a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that results from its human factors testing (HFT) of SC+ have been published in Hemodialysis International, a leading peer-reviewed journal for the renal community. SC+ was designed to empower patients to take control of their lives by making selfcare and home haemodialysis more accessible through a device that is small, simple to use, and powerful enough to deliver dialysis adequacy. This addresses the need for a dialysis system that is appealing to patients while also being suitable for use across the continuum of care, from the clinic to the home.

Click Here To Read The Full Press Release


March 2019: Quanta To Present At The 39th Annual Dialysis Conference

Quanta Dialysis Technologies, a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that the Company will be presenting at the 39th Annual Dialysis Conference (ADC), which runs from 16 to 19 March 2019, at the Sheraton Dallas Hotel, Texas, USA. Dr. Paul Komenda, Chief Medical Officer, will provide an update on SC+, explaining how it enables choice, efficiency and empowerment to both patients and physicians in the "Home Dialysis Machines" session on Monday, 18 March at 3:00pm. The presentation will be followed by a device demonstration at 3:45pm.

Click Here To Read The Full Press Release


February 2019: Quanta Strengthens Management Team In Preparation For Launch of SC+

Quanta Dialysis Technologies, a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces the expansion of its management team with the appointment of Steve Lane as Commercial Director, Chanel Allen-Megahey as Global Quality Assurance and Regulatory Affairs Director and Frank Herrmann as Marketing Director.

Click Here To Read The Full Press Release


January 2019: Quanta Appoints Dr. Paul Komenda As New Chief Medical Officer

Quanta Dialysis Technologies, today announces that the Company has appointed Dr. Paul Komenda as Chief Medical Officer. Dr. Komenda, Associate Professor of Medicine at the University of Manitoba, is a fellow of the American Society of Nephrology and has extensive clinical and academic experience. Dr. Komenda previously served on the Scientific Advisory Board of NxStage Medical. He gained his medical qualification in 2001 from the University of Manitoba and is a board certified Nephrologist. Dr. Komenda studied health economics at the University of Calgary, holds a Masters in Health Administration and is also the Medical Director of the Home Dialysis Program and the Seven Oaks General Hospital in Manitoba.

Click Here To Read The Full Press Release


View our past press releases